AstraZeneca's Blood Pressure Drug Wins U.S. Approval

AstraZeneca picks up FDA approval for hypertension drug

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we’re bringing you a special report: a fascinating look at how China’s growing role in global drug development is deeply dividing the U.S. biotech industry, with executives openly debating whether reliance on Chinese partners is a competitive necessity or a national security risk. Meanwhile, the FDA’s leadership shake…

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios - AstraZeneca (NYSE:AZN)

AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breast cancer treatment. Importance Rank:  1

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

(MedPage Today) -- The FDA approved the first-in-class oral aldosterone synthase inhibitor baxdrostat (Baxfendy) to treat adults with uncontrolled hypertension in combination with other antihypertensive drugs, AstraZeneca announced. Aldosterone...

AstraZeneca gets FDA OK for drug aimed at difficult-to-treat high blood pressure cases

AstraZeneca’s Baxfendy has been approved in the US for the treatment of hypertension in combination with other medications, to lower blood pressure in adults who are cannot adequately control their blood pressure.